Every S-1 that Artelo Biosciences, Inc. (ARTL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow ARTL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARTL filings page.
Artelo Biosciences, Inc. is registering 9,820,294 shares of common stock for resale by existing investors under a Form S-1. The shares relate to an March 27, 2026 private placement of 81,000 shares, 3,107,407 pre-funded warrant shares, 6,376,814 common warrant shares and 255,073 placement agent warrant shares.
Artelo will not receive proceeds from stockholder resales but may receive up to $21.5 million in gross proceeds if the warrants are exercised for cash, which it expects to use for working capital, general corporate purposes and repayment of bridge debt. Its stock trades on Nasdaq as “ARTL,” with a $6.61 closing price on April 6, 2026. The prospectus highlights significant dilution and resale overhang risks for existing holders.
Artelo Biosciences, Inc. is registering up to 4,273,519 shares of common stock for resale by Square Gate Capital Master Fund, LLC – Series 5 under an equity line of credit arrangement. These shares include 146,199 commitment-related shares and up to 4,127,320 shares that Artelo may sell to Square Gate over time.
Artelo will not receive any proceeds from Square Gate’s resale of these registered shares, but may raise up to $50,000,000 in gross proceeds from its discretionary sales of stock to Square Gate under the Equity Purchase Agreement. As of March 23, 2026, 736,127 shares of common stock were outstanding, so use of the facility could be significantly dilutive. The filing highlights risks around dilution, pricing at a discount to market, restrictions on other variable-rate financings, and the company’s need to maintain its Nasdaq listing under the symbol “ARTL.”
Artelo Biosciences, Inc. is seeking to raise equity capital through a primary offering of up to 1,641,587 shares of common stock or an equivalent number of pre-funded warrants, plus up to 1,707,251 shares of common stock underlying the pre-funded and placement agent warrants. The offering is on a best efforts basis at an assumed price of $7.31 per share, with no minimum proceeds required to close. Assuming all securities are sold at the assumed price, Artelo estimates net proceeds of about $10.9 million, to be used for working capital and general corporate purposes. The company’s pro forma cash would increase from $0.6 million to $11.5 million and stockholders’ equity from a deficit of $1.3 million to positive $9.6 million. The structure includes immediately exercisable pre-funded warrants with a $0.001 exercise price designed to help certain investors stay below 4.99% or 9.99% ownership thresholds, and placement agent warrants exercisable at 130% of the offering price. The company highlights meaningful dilution to new investors, the absence of a trading market for the warrants, and ongoing Nasdaq listing risk, while emphasizing that it has never paid dividends and does not expect to do so in the foreseeable future.
Artelo Biosciences, Inc. is offering up to 1,641,587 shares of common stock, or pre-funded warrants in lieu of shares, in a best efforts public offering at an assumed price of $7.31 per share. The company will also issue placement agent warrants to purchase up to 131,327 shares and is registering up to 1,772,914 shares of common stock underlying the pre-funded and placement agent warrants.
If fully sold at the assumed price, Artelo expects net proceeds of about $10.8 million, to be used for working capital and general corporate purposes. Shares outstanding would increase from 736,127 as of March 18, 2026 to 2,377,714, leading to immediate dilution, with an illustrative dilution of $4.07 per share to new investors. This is a no-minimum, best efforts deal, so actual proceeds may be substantially lower.
The offering structure includes low-exercise-price pre-funded warrants designed to help large investors stay below 4.99% or, at their option, 9.99% beneficial ownership caps. Artelo highlights risks including potential Nasdaq delisting if equity requirements are not met, volatility in its share price, and a going concern emphasis in its audited financial statements, even though this raise would improve stockholders’ equity from a deficit of $(1.3) million to a positive $9.5 million on an as-adjusted basis.
Artelo Biosciences, Inc. is registering up to 1,641,587 shares of common stock or pre-funded warrants, plus placement agent warrants for 131,327 shares and up to 1,772,914 underlying shares, in a best efforts primary offering. The securities are priced off an assumed public offering price of $7.31 per share.
Assuming all securities are sold at that price, Artelo estimates net proceeds of about $10.8 million, which it plans to use for working capital and general corporate purposes. Shares outstanding would rise to 2,377,714 from 736,127 as of March 18, 2026, leading to immediate and substantial dilution for new investors.
The deal includes pre-funded warrants with a $0.001 exercise price and 4.99% or 9.99% beneficial ownership limits, and unlisted placement agent warrants. The company highlights significant risks, including Nasdaq listing compliance, the absence of a minimum raise in this best efforts structure, and the speculative nature and limited liquidity of the warrants.
Artelo Biosciences, Inc. is registering up to 899,972 shares of common stock for resale by existing securityholders. These shares consist of 215,292 shares issuable upon conversion of convertible notes, 246,498 shares issuable upon exercise of warrants with a $6.24 exercise price, and 438,182 shares issuable upon exercise of warrants with a $3.40 exercise price. Artelo will not receive proceeds from the resale of these shares, but could receive approximately $3.0 million if all 684,680 warrant shares are exercised for cash. As of November 10, 2025, 2,018,746 shares of common stock were outstanding.
The company highlights significant risks, including substantial doubt about its ability to continue as a going concern, driven by cash of about $1.7 million, negative working capital of about $3.0 million, and a net loss of about $8.7 million for the nine months ended September 30, 2025. Artelo has received a Nasdaq notice for falling below the minimum stockholders’ equity requirement, and large potential resales under this prospectus could put additional pressure on the share price. The company also discloses volatility and liquidity risks tied to a $250,000 investment in the Solana cryptocurrency.